A rare case of advanced ovarian carcinoma who developed difficulty walking 25 days after treatment with weekly paclitaxel.
Although taxol has shown significant activity in advanced ovarian cancer, peripheral neuropathy is likely to become the major dose-limiting toxicity. We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol (80 mg/m(2)x3).
Kikuchi
Y
Y
Department of Obstetrics and Gynecology, National Defense Medical College, Namiki 3-2, Tokorozawa, Saitama 359-8513, Japan. QWL04765@nifty.ne.jp
Hiramatsu
H
H
Seto
H
H
Kita
T
T
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D002277:Carcinoma / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007866:Leg; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects*; D010146:Pain / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011434:Proprioception / Q000187:drug effects*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel